Skip to content

Clinical trials

Observational Hypertension trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hypertension Phase: Observational Country / region: United States Clear all

240 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20006
20012
20036
20044
20056
20067
20077
20087
200911
20106
20116
20127
201311
201411
20158
20164
201715
201812
20198
202014
202111
202210
20239
202411
202513
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed149
Recruiting32
Active, not recruiting13
Unknown status13
Terminated12
Withdrawn12
Enrolling by invitation6
Not yet recruiting2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)14
Brigham and Women's Hospital8
Duke University8
Weill Medical College of Cornell University8
University of Florida6
NYU Langone Health5
University of Alabama at Birmingham5
Wake Forest University Health Sciences5
Johns Hopkins University4
Mayo Clinic4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hypertension240
Diabetes Mellitus52
Cardiovascular Diseases40
Obesity29
Heart Failure23
Heart Diseases15
Stroke15
Diabetes Mellitus, Type 213
Renal Insufficiency, Chronic12
Asthma11

Trials

Showing 1 to 25 of 240. Each trial links to its page on Pharma Observatory.

140 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.